SCHEMBL1179136

SCHEMBL1179136

CCOc1nc(C)cc(C(=O)O)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALOX15 P16050 1/20 0.42
HIF1A Q16665 1/20 0.42
MAPK1 P28482 1/20 0.40
GPR35 Q9HC97 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
RBP4 P02753 1/20 0.37
MAPT P10636 1/20 0.37
EDNRB P24530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1178613 0.87 LMNA (0.42) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL1179821 0.82 LMNA (0.41) TSHRALDH1A1SMN1; SMN2LMNATDP1
SCHEMBL1179023 0.81 LMNA (0.44) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL1179070 0.80 LMNA (0.68) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL31069949 0.80 MCL1 (0.50) TSHRALDH1A1HSD17B10KDM4ECYP1A2
SCHEMBL8345854 0.79 MEN1 (0.42) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL1179956 0.79 MAPK8 (0.42) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL1179282 0.76 ALOX15 (0.47) TSHRALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL1178999 0.76 NPSR1 (0.39) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL1178998 0.76 LMNA (0.35) TSHRALDH1A1SMN1; SMN2HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD TSHR 3634/4885ALDH1A1 680/4885SMN1; SMN2 4171/4885
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 TSHR 2962/4885ALDH1A1 1658/4885SMN1; SMN2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.